FDA approves PharmaEssentia interferon drug for a rare type of blood ...
FDA approved PharmaEssentia's Besremi, the first interferon therapy for polycythemia vera, a rare blood cancer. Besremi, an engineered interferon alpha, reduces bone marrow blood cell production. Approved after a 7.5-year study showing 61% achieved normal blood levels, it carries risks like neuropsychiatric disorders and fetal harm.
Reference News
FDA approves PharmaEssentia interferon drug for a rare type of blood ...
FDA approved PharmaEssentia's Besremi, the first interferon therapy for polycythemia vera, a rare blood cancer. Besremi, an engineered interferon alpha, reduces bone marrow blood cell production. Approved after a 7.5-year study showing 61% achieved normal blood levels, it carries risks like neuropsychiatric disorders and fetal harm.